Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc11.6 | Oral Communications 11: Thyroid 2 | ECE2022

A new grading system for medullary thyroid cancer

Prete Alessandro , Gambale Carla , Torregrossa Liborio , Bottici Valeria , Cappagli Virginia , Basolo Fulvio , Elisei Rossella , Matrone Antonio

Introduction: medullary thyroid carcinoma (MTC) is a neuroendocrine thyroidal cancer. World Health Organization recognizes a grading system for almost all neuroendocrine tumors; however, a shared grading system for MTC is still lacking. We performed a clinical and pathological review of 257 MTCs to evaluate which histologic features have an impact on the disease specific survival and to propose a new grading system.Method: We retrospectively reviewed cli...

ea0081p472 | Thyroid | ECE2022

Cervical lymph nodes metastases in differentiated thyroid cancer: impact on clinical outcome

Gambale Carla , Matrone Antonio , Contartese Lea , Prete Alessandro , Viola David , Agate Laura , Molinaro Eleonora , Elisei Rossella

Background: Cervical lymph node metastases at histology are common findings in differentiated thyroid cancer (DTC); however, their impact on clinical outcome is debated.Material and method: 1332 DTC patients, performed the first 131 I treatment between January 2010 and September 2012 and were divided into 2 groups: absence (Nx/N0) or presence (N1) of lymph node metastases at histology. The latter group was further split in central compartment ...

ea0081p473 | Thyroid | ECE2022

Comparison of serum calcitonin and neck ultrasound sensitivities in identifying medullary thyroid carcinoma

Matrone Antonio , Gambale Carla , Prete Alessandro , Cappagli Virginia , Lorusso Loredana , Bottici Valeria , Vitti Paolo , Elisei Rossella

Background: Serum calcitonin (CT) is a very sensitive test for the diagnosis of medullary thyroid carcinoma (MTC). However, its routine dosage in patients with nodular thyroid disease is not recommended by all scientific societies. In addition, to optimize costs, it is only suggested in the case of suspicious nodules on ultrasound, indeterminate nodules at cytology or nodular goiter before surgery. The aim of the study is to evaluate the serum CT in a series of consecutive MTC...

ea0063p392 | Thyroid 1 | ECE2019

The presence of tall cells, even if

Matrone Antonio , Gambale Carla , Torregrossa Liborio , Valerio Laura , Molinaro Eleonora , Basolo Fulvio , Vitti Paolo , Elisei Rossella

Background: CV-PTC is often indolent with excellent long-term response, while TCV-PTC (≥50% of tall cells) have aggressive features and worse clinical behavior. Less is known about the clinical behavior of CV-PTC with tall cells <50% (TC/CV-PTC) that, so far, is considered as low risk tumor.Aim: To evaluate the histological presentation of CV-PTC, TC/CV-PTC, TCV-PTC and their clinical behavior after 6 years of follow up.M...

ea0084op-10-52 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Outcome of sporadic medullary thyroid cancer (MTC) patients with a biochemical persistent disease after initial treatment

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Torregrossa Liborio , Elisei Rossella , Matrone Antonio

Introduction: MTC is a rare neuroendocrine tumor arising from thyroid parafollicular cells. After initial treatment, patients should be divided according to their clinical status in cured, biochemical persistence (BIO) and structural persistence (STR) of the disease. Concerning BIO patients less is known about the structural disease appearance rate and the time elapsed between the first evaluation after surgery and the appearance of structural disease.Me...

ea0084ps1-03-22 | Thyroid Cancer CLINICAL 1 | ETA2022

Low risk differentiated thyroid carcinoma (DTC) can be safely treated with thyroidectomy alone: real-life experience in a medium-long term follow-up

Faranda Alessio , Gambale Carla , Prete Alessandro , Contartese Lea , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: Since 2006 according to the European consensus for the management of patients with DTC, in tumors ≤ 1 cm, treatment with thyroidectomy alone without 131I treatment was suggested. Therefore, in our institution, we applied this suggestion in clinical practice, although prospective studies were not still available. Aim of this study is to evaluate the rate of the events occurring in a medium-long term follow-up.Patients and Meth...

ea0084ps3-14-125 | Thyroid Cancer CLINICAL 2 | ETA2022

Lymph nodes metastases in differentiated thyroid cancer patients: understanding their impact on the clinical outcome

Matrone Antonio , Gambale Carla , Contartese Lea , Prete Alessandro , Faranda Alessio , Molinaro Eleonora , Elisei Rossella

Background: Lymph node metastases at histology (pN1) are usual findings in differentiated thyroid cancer (DTC) patients. Their detection has an impact on the extent of surgery, the further treatments after surgery, and on the clinical outcome.Material and method: We evaluated data of 1332 consecutive DTC patients who performed the first 131I treatment between January 2010 and September 2012. According to their pN status, they were divided into...

ea0084ps1-03-21 | Thyroid Cancer CLINICAL 1 | ETA2022

Risk of structural recurrence in differentiated thyroid carcinoma (DTC) patients without evidence of disease after initial treatment: insights into risk factors and comparison with american thyroid association guidelines

Contartese Lea , Gambale Carla , Prete Alessandro , Puleo Luciana , Cappagli Virginia , Lorusso Loredana , Agate Laura , Molinaro Eleonora , Elisei Rossella , Matrone Antonio

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...

ea0084ps3-15-140 | Thyroid Cancer Diagnosis & Treatment | ETA2022

Basal calcitonin as guide for an early and safe thyroid surgery in RET gene carriers

Prete Alessandro , Gambale Carla , Bottici Valeria , Cappagli Virginia , Matrone Antonio , Materazzi Gabriele , Basolo Fulvio , Romei Cristina , Elisei Rossella

Introduction: Virtually all familial cases of Medullary Thyroid Carcinoma (MTC) have a RET germline mutation. Subjects harboring RET germline mutation without unaware of their condition are defined gene carriers (GC). Thyroid surgery timing is decided upon RET mutation and calcitonin levels (both basal, bCT, and stimulated, sCT). However, bCT and sCT thresholds for planning thyroid surgery have not been established, yet.Methods...

ea0084ps1-03-20 | Thyroid Cancer CLINICAL 1 | ETA2022

Changes in clinical status after second 131I treatment in patients with differentiated thyroid cancer (dtc) not cured with the initial treatment

Gambale Carla , Matrone Antonio , Bottaro Valeria , Prete Alessandro , Faranda Alessio , Contartese Lea , Bianchi Francesca , Torregrossa Liborio , Basolo Fulvio , Molinaro Eleonora , Elisei Rossella

Objectives: Currently 131I treatment after surgery is suggested in selected intermediate-risk and in high-risk patients with DTC. In patients with radio-avid structural disease and in those with biochemical disease a second 131I treatment could be considered. However data about the impact of the second 131I treatment on clinical status remains controversial.Methods: Clinical data of 231 DTC patients followed at the Unit o...